Janux Therapeutics to Present at Upcoming March Investor Conferences

Author's Avatar
Mar 01, 2022

Janux+Therapeutics%2C+Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in three upcoming investor conferences: